

Title (en)
ANTISENSE COMPOUNDS TARGETING LEUCINE-RICH REPEAT KINASE 2 (LRRK2) FOR THE TREATMENT OF PARKINSONS DISEASE

Title (de)
ANTISENSE-VERBINDUNGEN GEGEN LEUCINREICHE REPEAT-KINASE 2 (LRRK2) ZUR BEHANDLUNG DER PARKINSONSCHEN KRANKHEIT

Title (fr)
COMPOSÉS ANTISENS CIBLANT UNE KINASE 2 À RÉPÉTITION RICHE EN LEUCINE (LRRK2) POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

Publication
EP 3724335 A1 20201021 (EN)

Application
EP 18830581 A 20181210

Priority
• US 201715837926 A 20171211
• US 2018064693 W 20181210

Abstract (en)
[origin: WO2019118325A1] The present disclosure relates generally to compounds comprising oligonucleotides complementary to Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript Certain such compounds are useful for hybridising to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript In, certain embodiments such compounds are used to treat one or more symptoms associated with Parkinson's disease.

IPC 8 full level
C12N 15/113 (2010.01)

CPC (source: EP)
C12N 9/12 (2013.01); **C12N 15/1137** (2013.01); **C12Y 207/11001** (2013.01); **C12N 2310/11** (2013.01); **C12N 2310/3233** (2013.01); **C12N 2320/33** (2013.01)

Citation (search report)
See references of WO 2019118325A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2019118325 A1 20190620; EP 3724335 A1 20201021

DOCDB simple family (application)
US 2018064693 W 20181210; EP 18830581 A 20181210